GSK plc (NYSE:GSK – Free Report) – Stock analysts at Zacks Research lifted their Q3 2023 earnings estimates for GSK in a note issued to investors on Wednesday, August 9th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will post earnings of $0.92 per share for the quarter, up from their prior forecast of $0.91. The consensus estimate for GSK’s current full-year earnings is $3.85 per share. Zacks Research also issued estimates for GSK’s Q4 2023 earnings at $0.89 EPS, FY2023 earnings at $3.67 EPS, Q2 2024 earnings at $0.87 EPS, Q3 2024 earnings at $1.06 EPS, Q4 2024 earnings at $0.96 EPS, FY2024 earnings at $3.75 EPS, Q1 2025 earnings at $1.15 EPS, Q2 2025 earnings at $0.96 EPS and FY2025 earnings at $4.34 EPS.
Several other analysts have also issued reports on GSK. HSBC began coverage on shares of GSK in a research report on Friday, July 14th. They issued a “reduce” rating on the stock. StockNews.com lowered shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Four research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $1,527.50.
GSK Stock Up 0.7 %
GSK opened at $35.33 on Friday. The company’s 50-day moving average price is $34.97 and its two-hundred day moving average price is $35.37. GSK has a twelve month low of $28.47 and a twelve month high of $39.74. The company has a quick ratio of 0.63, a current ratio of 0.88 and a debt-to-equity ratio of 1.28. The stock has a market cap of $72.34 billion, a price-to-earnings ratio of 4.00, a PEG ratio of 1.75 and a beta of 0.67.
Institutional Trading of GSK
A number of hedge funds and other institutional investors have recently bought and sold shares of GSK. Genus Capital Management Inc. bought a new position in shares of GSK in the 2nd quarter worth $511,000. Kayne Anderson Rudnick Investment Management LLC increased its holdings in shares of GSK by 2.6% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 20,794 shares of the pharmaceutical company’s stock worth $741,000 after buying an additional 535 shares during the last quarter. Regal Investment Advisors LLC increased its holdings in shares of GSK by 1.3% in the 2nd quarter. Regal Investment Advisors LLC now owns 26,354 shares of the pharmaceutical company’s stock worth $939,000 after buying an additional 348 shares during the last quarter. Cibc World Market Inc. increased its holdings in shares of GSK by 1.9% in the 2nd quarter. Cibc World Market Inc. now owns 297,295 shares of the pharmaceutical company’s stock worth $10,596,000 after buying an additional 5,669 shares during the last quarter. Finally, Baird Financial Group Inc. increased its holdings in shares of GSK by 40.1% in the 2nd quarter. Baird Financial Group Inc. now owns 116,420 shares of the pharmaceutical company’s stock worth $4,149,000 after buying an additional 33,296 shares during the last quarter. Institutional investors own 13.29% of the company’s stock.
GSK Cuts Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 18th will be issued a dividend of $0.3613 per share. This represents a $1.45 dividend on an annualized basis and a yield of 4.09%. The ex-dividend date of this dividend is Thursday, August 17th. GSK’s dividend payout ratio (DPR) is presently 16.10%.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Articles
- Five stocks we like better than GSK
- How to Invest in EV Charging Stations
- Investing in Coffee: 3 Great Strategies to Consider
- What is a Mid Cap Stock? How to Invest
- 5 Best Stocks to Buy in a Bear Market
- What is the Dow Jones Industrial Average (DJIA)?
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
